Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules

被引:37
作者
Dave, Vivek S. [1 ]
Gupta, Deepak [2 ]
Yu, Monica [2 ]
Phuong Nguyen [2 ]
Gupta, Sheeba Varghese [3 ]
机构
[1] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA
[2] Lake Eerie Coll Osteopath Med, Sch Pharm, Pharmaceut Sci, Bradenton, FL USA
[3] USF Coll Pharm, Dept Pharmaceut Sci, Tampa, FL USA
关键词
Permeability; BCS Class III; prodrugs; ion-pairing; counterion; nanotechnology; liposome; permeation enhancer; PEGYLATED LIPOSOMAL DOXORUBICIN; DRUG-DELIVERY; INTESTINAL-ABSORPTION; VIRUS NANOPARTICLES; ESTER PRODRUGS; DESIGN; PERMEATION; PHARMACOKINETICS; TOXICITY; ACID;
D O I
10.1080/03639045.2016.1269122
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based on their aqueous solubility and intestinal permeability. The BCS Class III compounds are hydrophilic molecules (high aqueous solubility) with low permeability across the biological membranes. While these compounds are pharmacologically effective, poor absorption due to low permeability becomes the rate-limiting step in achieving adequate bioavailability. Several approaches have been explored and utilized for improving the permeability profiles of these compounds. The approaches include traditional methods such as prodrugs, permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as nanoencapsulation and nanosizing. The most recent approaches include a combination/hybridization of one or more traditional approaches to improve drug permeability. While some of these approaches have been extremely successful, i.e. drug products utilizing the approach have progressed through the USFDA approval for marketing; others require further investigation to be applicable. This article discusses the commonly studied approaches for improving the permeability of BCS Class III compounds.
引用
收藏
页码:177 / 189
页数:13
相关论文
共 103 条
[1]  
Amidon G, 2006, MOL PHARM STRATEGIES
[2]  
AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321
[3]  
Amidon GL., 1987, BIOREV CARR DRUG, P243
[4]  
[Anonymous], 2009, THESIS U GLASGOW
[5]  
Apricus B, 2011, FEMPROX R PHASE 3 CL
[6]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[7]  
Attama AA, 2012, RECENT ADVANCES IN NOVEL DRUG CARRIER SYSTEMS, P107, DOI 10.5772/50486
[8]   Absorption Enhancers: Applications and Advances [J].
Aungst, Bruce J. .
AAPS JOURNAL, 2012, 14 (01) :10-18
[9]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[10]   Novel mechanisms and devices to enable successful transdermal drug delivery [J].
Barry, BW .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) :101-114